SummaryRMgm-482
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 20584882 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | M. Zhang; V. Nussenzweig |
Name Group/Department | Michael Heidelberger Division, Department of Pathology |
Name Institute | New York University School of Medicine |
City | New York |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-482 |
Principal name | PbeIK2(-) |
Alternative name | PbeIK2(-) ko1; PbeIK2(-) ko2 |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of salivary gland sporozoites are produced. Sporozoites showed reduced gliding motility and cell traversal capacity in vitro. Invasion of HepG2 cells in vitro was comparable to that of wild type parasites. Infectivity of sporozoites to mice was strongly reduced (as tested by intravenous injection of purified sporozoites or after infection of mice by mosquito bite). Salivary gland sporozoites show premature development into early liver stage forms (see further 'Additional remarks phenotype') |
Liver stage | Sporozoites showed reduced gliding motility and cell traversal capacity in vitro. Invasion of HepG2 cells in vitro was comparable to that of wild type parasites. Infectivity of sporozoites to mice was strongly reduced (as tested by intravenous injection of purified sporozoites or after infection of mice by mosquito bite). Salivary gland sporozoites show premature development into early liver stage forms (see further 'Additional remarks phenotype') |
Additional remarks phenotype | Mutant/mutation Three eIF2α kinases, IK1 (PF14_0423; eukaryotic initiation factor 2alpha kinase 1), IK2 (PfA0380w; PBANKA_020580; serine/threonine protein kinase, putative), and PK4 (PFF1370w; PBANKA_112690; protein kinase PK4), have been identified in Plasmodium (Fenell C et al. 2009. Malar J. 8, 99). See RMgm-532 for an independent P. berghei mutant lacking expression of IK2 (PBANKA_020580). Phenotype analyses of this mutant showed the following characteristics: Ookinete numbers (in vitro) reduced to 52% of wild type; Oocyst numbers (day 12-14) reduced to 20% of wild type; Sporozoites NOT different from wild type; Transmitted by mosquito bite. See below for a picture showing the location of the target regions used to disrupt PBANKA_020580 in the mutant described here and for mutant RMgm-532 Additional information Disruption of the P. falciparum ortholog has been attempted (Solyakov et al., 2011, Nat Commun, 2:565). After transfection with a KO vector a strong PCR signal diagnostic for gene disruption was observed in transfected populations indicating that this gene is not essential for asexual proliferation. Cloning will however be required to validate this interpretation for this |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0205800 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0107600 | ||||||||||||||||||||||||
Gene product | serine/threonine protein kinase, putative | ||||||||||||||||||||||||
Gene product: Alternative name | IK2; UIS1, up-regulated in infective sporozoites 1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption |
According to the (new) P. berghei assembly and annotation from GeneDB, only part of the gene was disrupted. Of the 8174bp CDS, a 5' fragment of 4367bp remains intact. The previous systematic id comprised 4 gene models: PB108190.00.0, PB102277.00.0, PB001255.02.0 and PB105212.00.0. Here, the disruption would result in a partial knock-out of PB102277.00.0 and complete knock-out of PB001255.02.0. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | PbeIK2 was replaced by double-crossover homologous recombination by the hDHFR selectable marker and a constitutively expressed GFP cassette | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |